Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 2/2014

01-06-2014 | Hot Topic

Clinical Considerations of Regenerative Medicine in Osteoporosis

Author: Hiromu Ito

Published in: Current Osteoporosis Reports | Issue 2/2014

Login to get access

Abstract

Osteoporosis-related fractures may severely limit activities of daily living and may require bed rest, which may become life threatening in elderly people. Osteoporosis has attracted much attention recently because of its severe effects on the daily activities of older people and because it is now treatable, thanks to recent advances in drug discovery. However, these medications have yet to reduce fully the number of fracture cases. On the other hand, declines in the number and function of osteoblasts and mesenchymal stem cells (MSCs) in the bone marrow and within the periosteum lead to reduced osteogenesis and bone formation. Thus, bone regeneration, through induction of MSCs, provides a rational therapeutic strategy for preventing or treating age-related osteoporosis. In this review, I summarize cell-related issues in osteoporosis, stem cell candidates for cell-based therapy, and possible therapeutic strategies for osteoporosis.
Literature
1.•
Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo). 2013;2013:125705. This paper reviews thoroughly osteoporosis and RANKL/OPG axis.
2.
3.
Prevention and management of osteoporosis. World Health Organization Technical Report Series, 2003; 921:1–164.
4.
David C, Confavreux CB, Mehsen N, Paccou J, Leboime A, Legrand E. Severity of osteoporosis: what is the impact of co-morbidities? Jt Bone Spine. 2010;77 Suppl 2:S103–6.CrossRef
5.
Katsara O, Mahaira LG, Iliopoulou EG, et al. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2011;20(9):1549–61.PubMedCrossRef
6.
Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115–37.PubMed
7.
8.
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–75.PubMedCrossRef
9.
Giampietro PF, McCarty C, Mukesh B, et al. The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: a pilot study utilizing the Marshfield Clinic Personalized Medicine Cohort. Osteoporos Int. 2010;21(3):467–77.PubMedCrossRef
10.
Urano T, Shiraki M, Ezura Y, et al. Association of a single-nucleotide polymorphism in low-density lipoprotein receptor-related protein 5 gene with bone mineral density. J Bone Miner Metab. 2004;22(4):341–5.PubMed
11.
Turgeman G, Zilberman Y, Zhou S, et al. Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice. J Cell Biochem. 2002;86(3):461–74.PubMedCrossRef
12.
Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154–6.PubMedCrossRef
13.
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–7.PubMedCrossRef
14.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.PubMedCrossRef
15.
Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–20.PubMedCrossRef
16.••
Mikami Y, Matsumoto T, Kano K, Toriumi T, Somei M, Honda MJ, et al. Current status of drug therapies for osteoporosis and the search for stem cells adapted for bone regenerative medicine. Anat Sci Int. 2014;89(1):1–10. This is one of the few reviews to describe potential therapies for osteoporosis using stem cells. PubMedCrossRef
17.•
Ito H. Chemokines in mesenchymal stem cell therapy for bone repair: a novel concept of recruiting mesenchymal stem cells and the possible cell sources. Mod Rheumatol. 2011;21(2):113–21.PubMedCrossRef
18.
Tavassoli M, Crosby WH. Transplantation of marrow to extramedullary sites. Science. 1968;161(3836):54–6. This paper reviews the current knowledge of the migration of mesenchymal stem cells. PubMedCrossRef
19.
Jones E, McGonagle D. Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxford). 2008;47(2):126–31.
20.
Gruber R, Mayer C, Bobacz K, Krauth MT, Graninger W, Luyten FP, et al. Effects of cartilage-derived morphogenetic proteins and osteogenic protein-1 on osteochondrogenic differentiation of periosteum-derived cells. Endocrinology. 2001;142(5):2087–94.PubMed
21.
Farrington-Rock C, Crofts NJ, Doherty MJ, Ashton BA, Griffin-Jones C, Canfield AE. Chondrogenic and adipogenic potential of microvascular pericytes. Circulation. 2004;110(15):2226–32.PubMedCrossRef
22.
Lee JY, Qu-Petersen Z, Cao B, et al. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol. 2000;150(5):1085–100.PubMedCentralPubMedCrossRef
23.
24.
Chen HT, Lee MJ, Chen CH, et al. Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med. 2012;16(3):582–93.PubMedCrossRef
25.
Lavoie JF, Biernaskie JA, Chen Y, Bagli D, Alman B, Kaplan DR, et al. Skin-derived precursors differentiate into skeletogenic cell types and contribute to bone repair. Stem Cells Dev. 2009;18(6):893–906.PubMedCrossRef
26.
Bi Y, Ehirchiou D, Kilts TM, et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med. 2007;13(10):1219–27.PubMedCrossRef
27.
Atesok K, Doral MN, Bilge O, Sekiya I. Synovial stem cells in musculoskeletal regeneration. J Am Acad Orthop Surg. 2013;21(4):258–9.PubMedCrossRef
28.••
Liu Y, Wu J, Zhu Y, Han J. Therapeutic application of mesenchymal stem cells in bone and joint diseases. Clin Exp Med. 2014;14(1):13–24. This is one of the few reviews to describe potential therapies for osteoporosis using stem cells. PubMedCrossRef
29.
Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem. 1994;56(3):283–94.PubMedCrossRef
30.
Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res. 1998;13(3):371–82.PubMedCrossRef
31.••
Marie PJ. Targeting integrins to promote bone formation and repair. Nat Rev Endocrinol. 2013;9(5):288–95. This paper describes one of the potential strategies for treatment of osteoporosis using stem cells. PubMedCrossRef
32.•
Guan M, Yao W, Liu R, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med. 2012;18(3):456–62. This presents one of the potential strategies for treatment of osteoporosis using stem cells. PubMedCentralPubMedCrossRef
33.•
Yao W, Guan M, Jia J, et al. Reversing bone loss by directing mesenchymal stem cells to bone. Stem Cells. 2013;31(9):2003–14. This paper presents one of the potential strategies for treatment of osteoporosis using stem cells. PubMedCentralPubMedCrossRef
Metadata
Title
Clinical Considerations of Regenerative Medicine in Osteoporosis
Author
Hiromu Ito
Publication date
01-06-2014
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 2/2014
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-014-0201-8

Other articles of this Issue 2/2014

Current Osteoporosis Reports 2/2014 Go to the issue

Nutrition, Exercise, and Lifestyle in Osteoporosis (C Weaver and S Ferrari, Section Editors)

Prenatal Calcium and Vitamin D Intake, and Bone Mass in Later Life

Nutrition, Exercise, and Lifestyle in Osteoporosis (C Weaver and S Ferrari, Section Editors)

The Effects of Flavonoids on Bone

Muscle and Bone (L Bonewald and M Harrick, Section Editors)

Endocrine Crosstalk Between Muscle and Bone

Biomechanics (M Silva and P Zysset, Section Editors)

Diabetes, Collagen, and Bone Quality

INVITED COMMENTARY

Bone Density Testing: Science, the Media, and Patient Care

Biomechanics (M Silva and P Zysset, Section Editors)

Ultrasound to Assess Bone Quality